The Biden administration on Thursday asserted its authority to seize the patents of certain costly medications in a new push to slash high drug prices and promote more pharmaceutical competition.

The administration unveiled a framework outlining the factors federal agencies should consider in deciding whether to use a controversial policy, known as march-in rights, to break the patents of drugs that were developed with federal funds but are not widely accessible to the public. For the first time, officials can now factor in a medication’s price — a change that could have big implications for drugmakers depending on how the government uses the powers.

“When drug companies won’t sell taxpayer-funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard said during a call with reporters Wednesday.

  • @psychothumbs
    link
    English
    691 year ago

    I think that’s more the media’s fault than the administration’s.

    • @frunch
      link
      391 year ago

      American citizens slammed with lower drug and education costs

      –there, now the media can run with it lol

      • @Broken_Monitor
        link
        81 year ago

        SLAM! As an American I demand more slams! Slam everything! Slam Trump! Slam Biden! Slam medicare! Slam insurance policies! Slam portmanteaus! Slam Bidenomics! Slam Obama care!

        SLLAAAAAAAAAAAAAAAAAAAAAAAMMMM!!!